Revolution in Alzheimer's treatment: Lecanemab receives EU approval!

Revolution in Alzheimer's treatment: Lecanemab receives EU approval!

Wasserburg am Inn, Deutschland - On April 15, 2025, the European drug organization granted approval for the Lecanemab drug for the treatment of Alzheimer's. This is a significant development in the fight against this serious illness, since Lecanemab is the first medicine that wants to actively combat the cause of Alzheimer's disease by reducing the deposition of amyloid plaques in the brain. Professor Dr. Janine Diehl-Schmid, chief physician in the center for geriatric medicine at the KBO-Inn-Salzach-Klinikum Wasserburg, expresses skepticism with regard to the effectiveness of this new drug, which is considered an important innovation, while the existing therapies only treat the symptoms.

dementia is a umbrella term for memory disorders and mental performance impairments, with Alzheimer's most common cause of dementia, about 70% of cases. The typical symptoms of Alzheimer's are initially lighter memory disorders that can often occur decades before the definitive diagnosis. The diagnosis is made in neurological practices or memory outpatient clinics by memory tests, blood tests and imaging methods of the brain.

effect and studies on Lecanemab

The experienced approaches in Alzheimer's treatment are traditionally based on acetylcholinesterase inhibitors and memant. However, these drugs do not bring healing, but only alleviate the symptoms. Lecanemab, on the other hand, shows in several studies, including the randomized, placebo-controlled study 201 with 856 patients that it can not only reduce amyloid plaques, but can also make a slowdown of cognitive expiry. The study results show dose -dependent reductions of brainloid after 12 and 18 months and the preservation of clinical treatment effects, even after the medication is stopped.

Therapy with Lecanemab is expected to be available in Germany in late 2025 or early 2026. Unfortunately, the drug is only suitable for patients in the early stage of Alzheimer's disease, which requires comprehensive diagnostic clarification, including nerve water examinations and special imaging. A genetic test before the treatment is also necessary to evaluate possible risks of side effects, especially in connection with the Apoe4 gene.

look into research

Despite progress, the search for effective treatment methods for dementia such as Alzheimer's is still a challenge. The approval of the last Alzheimer's medication in Germany has been more than 20 years ago. In the meantime, the antibody active ingredients Lecanemab and Donanemab, which are already available in the United States, are also being checked in the EU. Both drugs are designed to slow down the course of the disease in the early stage and are proof of the progress in Alzheimer's research that determine new approaches to combat this complex disease. Researchers are working intensively on therapy approaches worldwide for dementia, while the challenges remain.

Overall, the development of Lecanemab shows a promising step in the right direction, even if there are still many questions about long -term effects and optimal use. The findings from ongoing research are crucial for future treatment strategies for Alzheimer's patients.

Further information on the current developments in Alzheimer's research offers page alzheimer research , while detailed study results on Lecanemab and its effect in the publication pmc . For comprehensive reporting on current events, Rosenheim24 Important information.